TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1930699

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 226

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg with codeine 60 mg
Number of subjects: 226

Group type: COMPARATOR
Intervention: Zomepirac sodium 100 mg
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study: 7126493

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Insight-oriented therapy
Number of subjects: 5
Study: 31029475

Group type: EXPERIMENTAL
Intervention: Ketorolac-soaked bandage contact lens
Number of subjects: 70

Group type: COMPARATOR
Intervention: Regular soft bandage contact lens
Number of subjects: 70
Study: 29604620

Group type: EXPERIMENTAL
Intervention: Caricol®-Gastro (20 g, taken twice per day for 30 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27542921

Group type: EXPERIMENTAL
Intervention: Modified atWork intervention
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Original atWork intervention
Number of subjects: 1100
Study: 23925644

Group type: EXPERIMENTAL
Intervention: Fluticasone±salmeterol
Number of subjects: 89
Study: 23373239

Group type: EXPERIMENTAL
Intervention: Controlled synechiae technique
Number of subjects: 86

Group type: COMPARATOR
Intervention: Extended nasal packing in middle meatus until 1 week after surgery
Number of subjects: 86
Study: 20574204

Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP) implementation
Number of subjects: 0
Study: 18564687

Group type: EXPERIMENTAL
Intervention: Combined DTPw‐HBV/Hib vaccine administered at 1.5, 3, and 5 months after a birth dose of hepatitis B vaccine (HBV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined DTPw‐HBV/Hib vaccine
Number of subjects: 0
Study: 15958628

Group type: EXPERIMENTAL
Intervention: Marimastat 5 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Marimastat 20 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Marimastat 40 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Marimastat (all doses)
Number of subjects: 39
Study: 14633146

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 38

Group type: COMPARATOR
Intervention: Peritoneal dialysis
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hemodialysis vs Peritoneal dialysis
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hemodialysis vs Peritoneal dialysis (adjusted)
Number of subjects: 38
Study: 10501821

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPF) 600 mg t.i.d.
Number of subjects: 12
Study: 8865551

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound measurements at three visits, 7-14 days apart.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adjusted B-mode ultrasound measurements for site-specific reliability coefficients.
Number of subjects: 36
Study: 1510258

Group type: EXPERIMENTAL
Intervention: 27-gauge Quincke needle (n = 147)
Number of subjects: 298

Group type: COMPARATOR
Intervention: 24-gauge Sprotte needle (n = 151)
Number of subjects: 298
Study: 6423871

Group type: EXPERIMENTAL
Intervention: Induction group (received phenobarbital and glutathione)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Induction group
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study: 31415787

Group type: EXPERIMENTAL
Intervention: Potassium oxalate 10%
Number of subjects: 31

Group type: COMPARATOR
Intervention: Potassium oxalate 5%
Number of subjects: 31
Study: 30499486

Group type: EXPERIMENTAL
Intervention: Bioresonance therapy (BRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo procedures (control)
Number of subjects: 60
Study: 27255927

Group type: EXPERIMENTAL
Intervention: Teacher praise and reprimands during regular classroom lessons
Number of subjects: 570

Group type: COMPARATOR
Intervention: Good Behavior Game (GBG) implemented in half of the classrooms
Number of subjects: 570
Study: 24589870

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) as a coping strategy for smoking cessation
Number of subjects: 799
Study: 21983265

Group type: EXPERIMENTAL
Intervention: KRN5500
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19887157

Group type: EXPERIMENTAL
Intervention: Rumble strips on both sides of the centerline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sealed shoulders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current marking system (continuous lines)
Number of subjects: 0
Study: 17628912

Group type: EXPERIMENTAL
Intervention: Betamethasone 0.6 mg/day (n=8) or methylprednisolone 4 mg/day (n=6), single daily oral dose at 11.00 PM for 30 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Betamethasone 0.3 mg, single daily dose at 11.00 PM for six months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (seven normal females)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Post-treatment evaluation of 11 patients after therapy withdrawal
Number of subjects: 28
Study: 16149685

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, tid ac for 2 weeks)
Number of subjects: 35
Study: 12115016

Group type: EXPERIMENTAL
Intervention: Nimesulide suspension 1.5 mg/kg per dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 60
Study: 10399795

Group type: EXPERIMENTAL
Intervention: Glucocorticoid therapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vertebral compression fractures
Number of subjects: 80
Study: 7960533

Group type: EXPERIMENTAL
Intervention: ESWL monotherapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ESWL+PCNL combined therapy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Open stone surgery
Number of subjects: 43
Study: 3149152

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (150 mg, 75 mg twice daily)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Aspirin (3.6 g, 1.2 g three times daily)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 139

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 139
Study: 31326310

Group type: EXPERIMENTAL
Intervention: Visual assessment of mild emphysema
Number of subjects: 200

Group type: COMPARATOR
Intervention: Quantitative densitometric measurements
Number of subjects: 200
Study: 29741798

Group type: EXPERIMENTAL
Intervention: CARRII (Contraception and Alcohol Risk Reduction Internet Intervention)
Number of subjects: 71

Group type: COMPARATOR
Intervention: PE (static patient education website)
Number of subjects: 71
Study: 26830642

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 40
Study: 24847666

Group type: EXPERIMENTAL
Intervention: Breakfast skipping
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (with breakfast)
Number of subjects: 8
Study: 21975467

Group type: EXPERIMENTAL
Intervention: Structured goal elicitation using the Canadian Occupational Performance Measure
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 41
Study: 20554596

Group type: EXPERIMENTAL
Intervention: Postgraduate training (completed pharmacy residency or fellowship)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: No postgraduate training
Number of subjects: 1010
Study: 18567822

Group type: EXPERIMENTAL
Intervention: Fluoxetine (6 weeks administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (6 weeks administration)
Number of subjects: 20
Study: 15811211

Group type: EXPERIMENTAL
Intervention: gatifloxacin 0.3% administered BID
Number of subjects: 104

Group type: COMPARATOR
Intervention: gatifloxacin 0.3% administered QID
Number of subjects: 104
Study: 11919461

Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride gel administered over 10 seconds
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride gel administered over 2 seconds
Number of subjects: 100
Study: 10632986

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 9120744

Group type: EXPERIMENTAL
Intervention: Curosurf (modified porcine surfactant) administered at birth (80 mg/ml; dose 20 mg/kg)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Curosurf (modified porcine surfactant) administered at birth
Number of subjects: 287
Study: 1712850

Group type: EXPERIMENTAL
Intervention: Counselling and support for families of children with intellectual or multiple disabilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (randomly allocated)
Number of subjects: 0
Study: 6841943

Group type: EXPERIMENTAL
Intervention: Proglumide (50 mg/kg bolus, 50 mg/kg hour infusion, 100 mg/kg hour infusion, or combination)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cimetidine (2 mg/kg I.V. followed by 2 mg/kg hour)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Proglumide and Cimetidine
Number of subjects: 3
Study: 31990267

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for detecting infarction on non-contrast-enhanced CT images.
Number of subjects: 100
Study: 30664943

Group type: EXPERIMENTAL
Intervention: Working for You multi-level intervention (including iOTA program and workplace participatory program)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Working for You multi-level intervention
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1000
Study: 28152611

Group type: EXPERIMENTAL
Intervention: ABC intervention (10-session intervention to enhance parent-child interactions)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 52
Study: 25565322

Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency lateral branch neurotomy (CRF/LBN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham intervention (crossover group)
Number of subjects: 51
Study: 24362907

Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid (ALA) three times a day orally for 24 weeks
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 21767449

Group type: EXPERIMENTAL
Intervention: High-protein diet (30/0/70 % of energy from protein/carbohydrate/fat)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal-protein diet (12/55/33 % of energy from protein/carbohydrate/fat)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal-protein diet
Number of subjects: 22
Study: 19332156

Group type: EXPERIMENTAL
Intervention: Early feeding group (fluids on the first postoperative day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular feeding group (nothing by mouth until resolution of ileus)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular feeding group
Number of subjects: 120
Study: 17882685

Group type: EXPERIMENTAL
Intervention: New low‐ and ultra‐low‐dose oral preparations (0.3 mg conjugated equine estrogens and 0.5 mg estradiol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14 microg transdermal system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New progestogens (e.g. drospirenone, bioidentical progesterone, selective progesterone receptor modulators)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New female androgen patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulator/conjugated equine estrogen preparation combination
Number of subjects: 0
Study: 15083368

Group type: EXPERIMENTAL
Intervention: HRT with 0.625 mg oestrogen/day and 0.15 mg norgestrel
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 65
Study: 11228385

Group type: EXPERIMENTAL
Intervention: Pentavalent vaccine (DTP-Hib-HB) plus placebo (Group A, n=619)
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (DTP-HB) plus Hib vaccine (Group B, n=620)
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Bivalent vaccine (Hib-HB) plus DTP (Group C, n=226)
Number of subjects: 2156

Group type: EXPERIMENTAL
Intervention: Monovalent hepatitis B vaccine at birth followed by pentavalent vaccine (Group E, n=460)
Number of subjects: 2156

Group type: COMPARATOR
Intervention: Licensed control vaccines (DTP, Hib, HB) (Group D, n=231)
Number of subjects: 2156
Study: 9828772

Group type: EXPERIMENTAL
Intervention: Metipranolol (topical and systemic application)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metipranolol (topical application)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metipranolol (systemic application)
Number of subjects: 24
Study: 7666389

Group type: EXPERIMENTAL
Intervention: Use of entertainment films with guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Entertainment films
Number of subjects: 0
Study: 2107116

Group type: EXPERIMENTAL
Intervention: Operative gastrostomy (OG)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Endoscopic gastrostomy (PEG)
Number of subjects: 121
Study: 6106098

Group type: EXPERIMENTAL
Intervention: Diet B (carbohydrate 53%, fibre 54 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet A (carbohydrate 53%, fibre 16 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Diet C (carbohydrate 42%, fibre 20 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 8
Study: 31652771

Group type: EXPERIMENTAL
Intervention: Safe Fall training program
Number of subjects: 457

Group type: COMPARATOR
Intervention: Equilibrium exercises (Control)
Number of subjects: 457
Study: 27771172

Group type: EXPERIMENTAL
Intervention: 250mg resveratrol daily for 3 months
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 24467669

Group type: EXPERIMENTAL
Intervention: 3-month supervised exercise programme (32 men)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care (31 men)
Number of subjects: 63
Study: 24297381

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg qw
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg q2w
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg q2w
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Sarilumab ≥150 mg q2w
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 22421736

Group type: EXPERIMENTAL
Intervention: 33% Knowledge of Results (KR) frequency
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100% Knowledge of Results (KR) frequency
Number of subjects: 100
Study: 19131458

Group type: EXPERIMENTAL
Intervention: Familial risk information
Number of subjects: 118

Group type: COMPARATOR
Intervention: General risk factors alone
Number of subjects: 118
Study: 17454714

Group type: EXPERIMENTAL
Intervention: Proactive recruitment into telephone counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 14743286

Group type: EXPERIMENTAL
Intervention: Visible and infrared polarized (VIP) light (400‐3400 nm, 95% polarization, 40 mW cm(2), 12 J cm(2))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro irradiated blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of irradiated and non‐irradiated autologous blood 1:10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VIP light exposure
Number of subjects: 0
Study: 11202662

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9437309

Group type: EXPERIMENTAL
Intervention: ECCE/PC‐IOL
Number of subjects: 3400

Group type: COMPARATOR
Intervention: ICCE‐AG
Number of subjects: 3400

Group type: COMPARATOR
Intervention: ICCE
Number of subjects: 3400
Study: 8124972

Group type: EXPERIMENTAL
Intervention: Selective decontamination
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 59
Study: 12283724

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine instilled paracervically
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 46
Study: 4531657

Group type: EXPERIMENTAL
Intervention: Male experimenters with expectancy set
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Female experimenters with expectancy set
Number of subjects: 96

Group type: COMPARATOR
Intervention: Naive experimenters (control group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Experimenter sex effects
Number of subjects: 96

Group type: COMPARATOR
Intervention: Interaction effects of experimenter and subject sex
Number of subjects: 96
Study: 30120894

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Standard chemotherapy (control)
Number of subjects: 638
Study: 29162057

Group type: EXPERIMENTAL
Intervention: Go NAPSACC (intervention group, n=18)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Delayed access (control group, n=15)
Number of subjects: 33
Study: 25947117

Group type: EXPERIMENTAL
Intervention: Closed-suction drain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed passive gravity drain
Number of subjects: 0
Study: 23140661

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (100 mg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 21257305

Group type: EXPERIMENTAL
Intervention: Hospital follow-up plus EGP
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up plus EGP
Number of subjects: 299

Group type: COMPARATOR
Intervention: Hospital follow-up without EGP
Number of subjects: 299

Group type: COMPARATOR
Intervention: Telephone follow-up without EGP
Number of subjects: 299
Study: 18602331

Group type: EXPERIMENTAL
Intervention: Wearable audio-biofeedback system
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control conditions (eyes closed on solid surface, eyes open on foam cushion surface, eyes closed on foam cushion surface)
Number of subjects: 9
Study: 17685467

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 14971968

Group type: EXPERIMENTAL
Intervention: Evening performance (6 PM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morning performance (8 AM)
Number of subjects: 0
Study: 11720400

Group type: EXPERIMENTAL
Intervention: Swallowing reflex measured by latent time (LT) for swallowing following bolus injection of distilled water.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Swallowing reflex measured by inspiratory suppression time (IST) from swallowing termination to the next onset of inspiration.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Swallowing reflex measured by threshold for evoking the swallowing response in terms of a volume of water (TV).
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation of nocturnal nadir SaO2 with swallowing reflex measures.
Number of subjects: 24
Study: 9415000

Group type: EXPERIMENTAL
Intervention: Localized calf skeletal muscle training (unilateral calf plantar flexion exercise)
Number of subjects: 7
Study: 8326162

Group type: EXPERIMENTAL
Intervention: Five-drug combination (metoclopramide, thiethylperazine, diphenhydramine, dexamethasone, diazepam)
Number of subjects: 32
Study: 3511346

Group type: EXPERIMENTAL
Intervention: Naloxone 2 mg IV
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study: 30377185

Group type: EXPERIMENTAL
Intervention: mDiabetes
Number of subjects: 172

Group type: COMPARATOR
Intervention: pLogbook
Number of subjects: 172
Study: 28987804

Group type: EXPERIMENTAL
Intervention: Revefenacin 350 μg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Revefenacin 700 μg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ipratropium 500 μg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Revefenacin 22 μg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 26560987

Group type: EXPERIMENTAL
Intervention: 20 mg oral sustained release morphine daily for 4 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 4 days
Number of subjects: 38
Study: 24317352

Group type: EXPERIMENTAL
Intervention: Prehospital 'plasma-first' resuscitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh frozen plasma delivered early in the emergency department
Number of subjects: 0
Study: 23158425

Group type: EXPERIMENTAL
Intervention: Epidural space preloaded with epinephrine (1:200 000)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 100
Study: 20018804

Group type: EXPERIMENTAL
Intervention: Diet with 5% C(4) sugars
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diet with 16% C(4) sugars
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diet with 32% C(4) sugars
Number of subjects: 5
Study: 16615036

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine adjunctive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostics for confounding in PK/PD models
Number of subjects: 0
Study: 16086046

Group type: EXPERIMENTAL
Intervention: Glutamine (2 g/m²/dose, maximum 4 g, twice daily until 28 days post transplant)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Glycine (control group)
Number of subjects: 120
Study: 11897246

Group type: EXPERIMENTAL
Intervention: BCAA 1.5 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BCAA 3.0 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BCAA 6.0 g
Number of subjects: 16

Group type: COMPARATOR
Intervention: BCAA (middle-dose group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BCAA (1.5 and 3.0 g)
Number of subjects: 16
Study: 10451133

Group type: EXPERIMENTAL
Intervention: Femoral 3-in-1 block with 40 ml ropivacaine 0.2% and 20 ml ropivacaine 0.2% infiltration at the end of surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 44
Study: 7587906

Group type: EXPERIMENTAL
Intervention: VM-26 plus CCNU
Number of subjects: 34

Group type: COMPARATOR
Intervention: Chemotherapy protocol without VM-26 and CCNU
Number of subjects: 34
Study: 2112489

Group type: EXPERIMENTAL
Intervention: leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Number of subjects: 20